Literature DB >> 14613320

3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.

John M Sanders1, Aurora Ortiz Gómez, Junhong Mao, Gary A Meints, Erin M Van Brussel, Agnieszka Burzynska, Pawel Kafarski, Dolores González-Pacanowska, Eric Oldfield.   

Abstract

We report the activities of 62 bisphosphonates as inhibitors of the Leishmania major mevalonate/isoprene biosynthesis pathway enzyme, farnesyl pyrophosphate synthase. The compounds investigated exhibit activities (IC(50) values) ranging from approximately 100 nM to approximately 80 microM (corresponding to K(i) values as low as 10 nM). The most active compounds were found to be zoledronate (whose single-crystal X-ray structure is reported), pyridinyl-ethane-1-hydroxy-1,1-bisphosphonates or picolyl aminomethylene bisphosphonates. However, N-alicyclic aminomethylene bisphosphonates, such as incadronate (N-cycloheptyl aminomethylene bisphosphonate), as well as aliphatic aminomethylene bisphosphonates containing short (n = 4, 5) alkyl chains, were also active, with IC(50) values in the 200-1700 nM range (corresponding to K(i) values of approximately 20-170 nM). Bisphosphonates containing longer or multiple (N,N-) alkyl substitutions were inactive, as were aromatic species lacking an o- or m-nitrogen atom in the ring, or possessing multiple halogen substitutions or a p-amino group. To put these observations on a more quantitative structural basis, we used three-dimensional quantitative structure-activity relationship techniques: comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA), to investigate which structural features correlated with high activity. Training set results (N = 62 compounds) yielded good correlations with each technique (R(2) = 0.87 and 0.88, respectively), and were further validated by using a training/test set approach. Test set results (N = 24 compounds) indicated that IC(50) values could be predicted within factors of 2.9 and 2.7 for the CoMFA and CoMSIA methods, respectively. The CoMSIA fields indicated that a positive charge in the bisphosphonate side chain and a hydrophobic feature contributed significantly to activity. Overall, these results are of general interest since they represent the first detailed quantitative structure-activity relationship study of the inhibition of an expressed farnesyl pyrophosphate synthase enzyme by bisphosphonate inhibitors and that the activity of these inhibitors can be predicted within about a factor of 3 by using 3D-QSAR techniques.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14613320     DOI: 10.1021/jm0302344

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

1.  Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate.

Authors:  Aurora Ortiz-Gómez; Carmen Jiménez; Antonio M Estévez; Juana Carrero-Lérida; Luis M Ruiz-Pérez; Dolores González-Pacanowska
Journal:  Eukaryot Cell       Date:  2006-07

2.  Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.

Authors:  Cammy K-M Chen; Michael P Hudock; Yonghui Zhang; Rey-Ting Guo; Rong Cao; Joo Hwan No; Po-Huang Liang; Tzu-Ping Ko; Tao-Hsin Chang; Shiou-Chi Chang; Yongcheng Song; Jordan Axelson; Anup Kumar; Andrew H-J Wang; Eric Oldfield
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

Review 3.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

4.  The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.

Authors:  Kathryn L Kavanagh; Kunde Guo; James E Dunford; Xiaoqiu Wu; Stefan Knapp; Frank H Ebetino; Michael J Rogers; R Graham G Russell; Udo Oppermann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-09       Impact factor: 11.205

Review 5.  Farnesyl pyrophosphate synthase modulators: a patent review (2006 - 2010).

Authors:  Shuting Sun; Charles E McKenna
Journal:  Expert Opin Ther Pat       Date:  2011-06-25       Impact factor: 6.674

6.  Probing the opportunities for designing anthelmintic leads by sub-structural topology-based QSAR modelling.

Authors:  Prabodh Ranjan; Mohd Athar; Prakash Chandra Jha; Kari Vijaya Krishna
Journal:  Mol Divers       Date:  2018-04-02       Impact factor: 2.943

7.  Molecular factors governing inhibition of arylimidamides against Leishmania: conservative computational modeling to improve chemotherapies.

Authors:  Catharine J Collar; Xiaohua Zhu; Karl Werbovetz; David W Boykin; W David Wilson
Journal:  Bioorg Med Chem       Date:  2011-06-16       Impact factor: 3.641

8.  Pharmacophore modeling, docking and molecular dynamics to identify Leishmania major farnesyl pyrophosphate synthase inhibitors.

Authors:  Larissa de Mattos Oliveira; Janay Stefany Carneiro Araújo; David Bacelar Costa Junior; Isis Bugia Santana; Angelo Amâncio Duarte; Franco Henrique Andrade Leite; Raquel Guimarães Benevides; Manoelito Coelho Dos Santos Junior
Journal:  J Mol Model       Date:  2018-10-16       Impact factor: 1.810

9.  Bisphosphonate inhibition of a Plasmodium farnesyl diphosphate synthase and a general method for predicting cell-based activity from enzyme data.

Authors:  Dushyant Mukkamala; Joo Hwan No; Lauren M Cass; Ting-Kai Chang; Eric Oldfield
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

10.  Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.

Authors:  Yongcheng Song; Julian M W Chan; Zev Tovian; Aaron Secrest; Eva Nagy; Kilannin Krysiak; Kyle Bergan; Michael A Parniak; Eric Oldfield
Journal:  Bioorg Med Chem       Date:  2008-08-27       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.